- Home
- CBAT vs PLRX Comparison
CBAT vs PLRX Comparison
Compare CBAT & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBAT
- PLRX
- Stock Information
- Founded
- CBAT 1999
- PLRX 2015
- Country
- CBAT China
- PLRX United States
- Employees
- CBAT N/A
- PLRX N/A
- Industry
- CBAT Industrial Machinery/Components
- PLRX Biotechnology: Pharmaceutical Preparations
- Sector
- CBAT Miscellaneous
- PLRX Health Care
- Exchange
- CBAT Nasdaq
- PLRX Nasdaq
- Market Cap
- CBAT 90.4M
- PLRX 93.3M
- IPO Year
- CBAT N/A
- PLRX 2020
- Fundamental
- Price
- CBAT $0.96
- PLRX $1.50
- Analyst Decision
- CBAT
- PLRX Hold
- Analyst Count
- CBAT 0
- PLRX 10
- Target Price
- CBAT N/A
- PLRX $3.93
- AVG Volume (30 Days)
- CBAT 211.1K
- PLRX 370.4K
- Earning Date
- CBAT 11-11-2025
- PLRX 11-06-2025
- Dividend Yield
- CBAT N/A
- PLRX N/A
- EPS Growth
- CBAT N/A
- PLRX N/A
- EPS
- CBAT N/A
- PLRX N/A
- Revenue
- CBAT $145,462,366.00
- PLRX N/A
- Revenue This Year
- CBAT N/A
- PLRX N/A
- Revenue Next Year
- CBAT $60.02
- PLRX N/A
- P/E Ratio
- CBAT N/A
- PLRX N/A
- Revenue Growth
- CBAT N/A
- PLRX N/A
- 52 Week Low
- CBAT $0.57
- PLRX $1.10
- 52 Week High
- CBAT $1.30
- PLRX $16.10
- Technical
- Relative Strength Index (RSI)
- CBAT 53.61
- PLRX 48.98
- Support Level
- CBAT $0.87
- PLRX $1.46
- Resistance Level
- CBAT $1.02
- PLRX $1.55
- Average True Range (ATR)
- CBAT 0.04
- PLRX 0.07
- MACD
- CBAT 0.01
- PLRX 0.00
- Stochastic Oscillator
- CBAT 50.00
- PLRX 65.52
About CBAT CBAK Energy Technology Inc.
CBAK Energy Technology Inc is engaged in the manufacture, commercialization, and distribution of a variety of standard and customized lithium and sodium high-power rechargeable batteries. The batteries are used in light electric vehicles, electric vehicles, energy storage devices, and other high-power applications. The company has two operating segments: CBAK, which derives maximum revenue, and includes the manufacturing, commercialization, and distribution of various standard and customized lithium-ion rechargeable batteries; and the Hitrans segment, which includes the development and manufacturing of NCM precursor and cathode materials. Geographically, the company derives its key revenue from Mainland China, followed by Europe and other regions.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.